References:
1. Staerk, L., et al., Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ, 2018. 361 : p. k1453.
2. Wolf, P.A., R.D. Abbott, and W.B. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991. 22 (8): p. 983-8.
3. Michaud, G.F. and W.G. Stevenson, Atrial Fibrillation. New England Journal of Medicine, 2021. 384 (4): p. 353-361.
4. January, C.T., et al., 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation, 2019. 140 (2): p. e125-e151.
5. Westerman, S. and N. Wenger, Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes. Curr Cardiol Rev, 2019. 15 (2): p. 136-144.
6. Emdin, C.A., et al., Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ (Clinical research ed.), 2016. 532 : p. h7013-h7013.
7. Schmidt, B., et al., Incidence of pericardial effusion after left atrial appendage closure: The impact of underlying heart rhythm-Data from the EWOLUTION study. J Cardiovasc Electrophysiol, 2018. 29 (7): p. 973-978.
8. Holmes, D.R., Jr., et al., Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol, 2014. 64 (1): p. 1-12.
9. Holmes, D.R., et al., Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet, 2009. 374 (9689): p. 534-42.
10. Darden, D., et al., Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry. JAMA Cardiol, 2021.
11. (HCUP), H.C.a.U.P. NRD Overview . 07/15/2021]; Available from: https://www.hcup-us.ahrq.gov/nrdoverview.jsp.
12. StataCorp, Stata Statistical Software: Release 16 . 2019, College Station, TX: StataCorp LLC.
13. Freeman, J.V., et al., The NCDR Left Atrial Appendage Occlusion Registry. J Am Coll Cardiol, 2020. 75 (13): p. 1503-1518.
14. Wintgens, L.I.S., et al., The WATCHMAN left atrial appendage closure device for patients with atrial fibrillation: current status and future perspectives. Expert Review of Medical Devices, 2020.17 (7): p. 615-626.
15. Veinot, J.P., et al., Anatomy of the normal left atrial appendage: a quantitative study of age-related changes in 500 autopsy hearts: implications for echocardiographic examination. Circulation, 1997. 96 (9): p. 3112-3115.
16. Boucebci, S., et al., Assessment of normal left atrial appendage anatomy and function over gender and ages by dynamic cardiac CT. Eur Radiol, 2016. 26 (5): p. 1512-20.
17. Elzeneini, M., A. Elshazly, and A.E.M. Nayel, The left atrial appendage morphology and gender differences by multi-detector computed tomography in an Egyptian population. Egypt Heart J, 2020.72 (1): p. 38.
18. Sandgren, T., et al., The diameter of the common femoral artery in healthy human: influence of sex, age, and body size. Journal of vascular surgery, 1999. 29 (3): p. 503-510.
19. Osman, M., et al., Sex-stratified analysis of the safety of percutaneous left atrial appendage occlusion. Catheter Cardiovasc Interv, 2021. 97 (5): p. 885-892.